help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by OLSCHEWSKI, H.
Right arrow Articles by SEEGER, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by OLSCHEWSKI, H.
Right arrow Articles by SEEGER, W.

Am. J. Respir. Crit. Care Med., Volume 160, Number 2, August 1999, 600-607

Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis

HORST OLSCHEWSKI, H. ARDESCHIR GHOFRANI, DIETER WALMRATH, RALPH SCHERMULY, BETTINA TEMMESFELD-WOLLBRÜCK, FRIEDRICH GRIMMINGER, and WERNER SEEGER

Depatment of Internal Medicine II, Justus-Liebig-University, Giessen, Germany

Pulmonary hypertension is a life-threatening complication of lung fibrosis. Vasodilator therapy is difficult owing to systemic side effects and pulmonary ventilation-perfusion mismatch. We compared the effects of intravenous prostacyclin and inhaled NO and aerosolized prostacyclin in randomized order and, in addition, tested for effects of oxygen and systemic calcium antagonists (CAAs) in eight patients with lung fibrosis and pulmonary hypertension. Aerosolized prostaglandin (PG)I2 caused preferential pulmonary vasodilatation with a decrease in mean pulmonary arterial pressure from 44.1 ± 4.2 to 31.6 ± 3.1 mm Hg, and pulmonary vascular resistance (RL) from 810 ± 226 to 386 ± 69 dyn · s · cm-5 (p < 0.05, respectively). Systemic arterial pressure, arterial oxygen saturation, and pulmonary right-to-left shunt flow, measured by multiple inert gas analysis, were not significantly changed. Inhaled NO similarly resulted in selective pulmonary vasodilatation, with RL decreasing from 726 ± 217 to 458 ± 81 dyn · s · cm-5. In contrast, both intravenous PGI2 and CAAs were not pulmonary selective, resulting in a significant drop in arterial pressure. In addition, PGI2 infusion caused a marked increase in shunt flow. Long-term therapy with aerosolized iloprost (long-acting PGI2 analog) resulted in unequivocal clinical improvement from a state of immobilization and severe resting dyspnea in a patient with decompensated right heart failure. We concluded that, in pulmonary hypertension secondary to lung fibrosis, aerosolization of PGI2 or iloprost causes marked pulmonary vasodilatation with maintenance of gas exchange and systemic arterial pressure. Long-term therapy with inhaled iloprost may be life saving in decompensated right heart failure from pulmonary hypertension secondary to lung fibrosis.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
M. Gomberg-Maitland and H. Olschewski
Prostacyclin therapies for the treatment of pulmonary arterial hypertension
Eur. Respir. J., April 1, 2008; 31(4): 891 - 901.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H. H. Leuchte, T. Meis, M. El-Nounou, J. Michalek, and J. Behr
Inhalation of endothelin receptor blockers in pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L772 - L777.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. F. Shorr, J. L. Wainright, C. S. Cors, C. J. Lettieri, and S. D. Nathan
Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
Eur. Respir. J., October 1, 2007; 30(4): 715 - 721.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
N. M. Patel, D. J. Lederer, A. C. Borczuk, and S. M. Kawut
Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Chest, September 1, 2007; 132(3): 998 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. D. Nathan, P. W. Noble, and R. M. Tuder
Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension: Connecting the Dots
Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 875 - 880.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Gunther, B. Enke, P. Markart, P. Hammerl, H. Morr, J. Behr, G. Stahler, W. Seeger, F. Grimminger, I. Leconte, et al.
Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study
Eur. Respir. J., April 1, 2007; 29(4): 713 - 719.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
K. A. Fisher, D. M. Serlin, K. C. Wilson, R. E. Walter, J. S. Berman, and H. W. Farber
Sarcoidosis-Associated Pulmonary Hypertension: Outcome With Long-term Epoprostenol Treatment.
Chest, November 1, 2006; 130(5): 1481 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
H. A. Ghofrani, R. Voswinckel, F. Reichenberger, N. Weissmann, R. T. Schermuly, W. Seeger, and F. Grimminger
Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies
Cardiovasc Res, October 1, 2006; 72(1): 30 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. Roizenblatt, C. Guilleminault, D. Poyares, F. Cintra, A. Kauati, and S. Tufik
A Double-blind, Placebo-Controlled, Crossover Study of Sildenafil in Obstructive Sleep Apnea.
Arch Intern Med, September 18, 2006; 166(16): 1763 - 1767.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. H. Leuchte, R. A. Baumgartner, M. E. Nounou, M. Vogeser, C. Neurohr, M. Trautnitz, and J. Behr
Brain Natriuretic Peptide Is a Prognostic Parameter in Chronic Lung Disease
Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 744 - 750.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
H Nunes, M Humbert, F Capron, M Brauner, O Sitbon, J-P Battesti, G Simonneau, and D Valeyre
Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis
Thorax, January 1, 2006; 61(1): 68 - 74.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. T. Schermuly, H. Yilmaz, H. A. Ghofrani, K. Woyda, S. Pullamsetti, A. Schulz, T. Gessler, R. Dumitrascu, N. Weissmann, F. Grimminger, et al.
Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 358 - 363.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. E Baker and R. H. Hockman
Inhaled Iloprost in Pulmonary Arterial Hypertension
Ann. Pharmacother., July 1, 2005; 39(7): 1265 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Dembinski, W. Brackhahn, D. Henzler, A. Rott, R. Bensberg, R. Kuhlen, and R. Rossaint
Cardiopulmonary effects of iloprost in experimental acute lung injury
Eur. Respir. J., January 1, 2005; 25(1): 81 - 87.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al.
Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. H. Leuchte, C. Neurohr, R. Baumgartner, M. Holzapfel, W. Giehrl, M. Vogeser, and J. Behr
Brain Natriuretic Peptide and Exercise Capacity in Lung Fibrosis and Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 360 - 365.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. B. Badesch, V. V. McLaughlin, M. Delcroix, C. Vizza, H. Olschewski, O. Sitbon, and R. J. Barst
Prostanoid therapy for pulmonary arterial hypertension
J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 56S - 61S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. Olschewski, B. Rohde, J. Behr, R. Ewert, T. Gessler, H. A. Ghofrani, and T. Schmehl
Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension
Chest, October 1, 2003; 124(4): 1294 - 1304.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. A. Kandler, K. von der Hardt, S. Mahfoud, M. Chada, E. Schoof, T. Papadopoulos, W. Rascher, and J. Dotsch
Pilot Intervention: Aerosolized Adrenomedullin Reduces Pulmonary Hypertension
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1021 - 1026.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
H. A. Ghofrani, F. Rose, R. T. Schermuly, H. Olschewski, R. Wiedemann, A. Kreckel, N. Weissmann, S. Ghofrani, B. Enke, W. Seeger, et al.
Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension
J. Am. Coll. Cardiol., July 2, 2003; 42(1): 158 - 164.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J.A. Barbera, V.I. Peinado, and S. Santos
Pulmonary hypertension in chronic obstructive pulmonary disease
Eur. Respir. J., May 1, 2003; 21(5): 892 - 905.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
A. Martineau, G. Arcand, P. Couture, D. Babin, L. P. Perreault, and A. Denault
Transesophageal Echocardiographic Diagnosis of Carbon Dioxide Embolism During Minimally Invasive Saphenous Vein Harvesting and Treatment with Inhaled Epoprostenol
Anesth. Analg., April 1, 2003; 96(4): 962 - 964.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. Hache, A. Denault, S. Belisle, D. Robitaille, P. Couture, P. Sheridan, M. Pellerin, D. Babin, N. Noel, M.-C. Guertin, et al.
Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery
J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 642 - 649.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. T. Schermuly, A. Schulz, H. A. Ghofrani, A. Meidow, F. Rose, A. Roehl, N. Weissmann, M. Hildebrand, J. Kurz, F. Grimminger, et al.
Pharmacokinetics and Metabolism of Infused versus Inhaled Iloprost in Isolated Rabbit Lungs
J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 741 - 745.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
N. Galie, A. Manes, and A. Branzi
The new clinical trials on pharmacological treatment in pulmonary arterial hypertension
Eur. Respir. J., October 1, 2002; 20(4): 1037 - 1049.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Olschewski, G. Simonneau, N. Galie, T. Higenbottam, R. Naeije, L. J. Rubin, S. Nikkho, R. Speich, M. M. Hoeper, J. Behr, et al.
Inhaled Iloprost for Severe Pulmonary Hypertension
N. Engl. J. Med., August 1, 2002; 347(5): 322 - 329.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. C. Blumberg, G. A. J. Riegger, and M. Pfeifer
Hemodynamic Effects of Aerosolized Iloprost in Pulmonary Hypertension at Rest and During Exercise*
Chest, May 1, 2002; 121(5): 1566 - 1571.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
H. A. Ghofrani, R. Wiedemann, F. Rose, H. Olschewski, R. T. Schermuly, N. Weissmann, W. Seeger, and F. Grimminger
Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension
Ann Intern Med, April 2, 2002; 136(7): 515 - 522.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
L. H. Clapp, P. Finney, S. Turcato, S. Tran, L. J. Rubin, and A. Tinker
Differential Effects of Stable Prostacyclin Analogs on Smooth Muscle Proliferation and Cyclic AMP Generation in Human Pulmonary Artery
Am. J. Respir. Cell Mol. Biol., February 1, 2002; 26(2): 194 - 201.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. T. SCHERMULY, E. KRUPNIK, H. TENOR, C. SCHUDT, N. WEISSMANN, F. ROSE, F. GRIMMINGER, W. SEEGER, D. WALMRATH, and H. A. GHOFRANI
Coaerosolization of Phosphodiesterase Inhibitors Markedly Enhances the Pulmonary Vasodilatory Response to Inhaled Iloprost in Experimental Pulmonary Hypertension . Maintenance of Lung Selectivity
Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1694 - 1700.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. Wiedemann, H. A. Ghofrani, N. Weissmann, R. Schermuly, K. Quanz, F. Grimminger, W. Seeger, and H. Olschewski
Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: Response to iloprost inhalation
J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1130 - 1136.
[Abstract] [Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
M. Hache, A. Y. Denault, S. Belisle, P. Couture, D. Babin, F. Tetrault, and J.-G. Guimond
Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit : [L'inhalation de prostacycline (PGI2) est un traitement complementaire efficace de l'hypertension pulmonaire et de l'hypoxie observees en salle d'operation et a l'unite des soins intensifs]
Can J Anesth, October 1, 2001; 48(9): 924 - 929.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
R. T. Schermuly, N. Weissmann, B. Enke, H. A. Ghofrani, W. G. Forssmann, F. Grimminger, W. Seeger, and D. Walmrath
Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension . Synergism upon Coapplication
Am. J. Respir. Cell Mol. Biol., August 1, 2001; 25(2): 219 - 225.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
T. Gessler, T. Schmehl, M.M. Hoeper, F. Rose, H.A. Ghofrani, H. Olschewski, F. Grimminger, and W. Seeger
Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension
Eur. Respir. J., January 1, 2001; 17(1): 14 - 19.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. Wharton, N. Davie, P. D. Upton, M. H. Yacoub, J. M. Polak, and N. W. Morrell
Prostacyclin Analogues Differentially Inhibit Growth of Distal and Proximal Human Pulmonary Artery Smooth Muscle Cells
Circulation, December 19, 2000; 102(25): 3130 - 3136.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. A. Krasuski, J. J. Warner, A. Wang, J. K. Harrison, V. F. Tapson, and T. M. Bashore
Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology
J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2204 - 2211.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. M. Hoeper, M. Schwarze, S. Ehlerding, A. Adler-Schuermeyer, E. Spiekerkoetter, J. Niedermeyer, M. Hamm, and H. Fabel
Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue
N. Engl. J. Med., June 22, 2000; 342(25): 1866 - 1870.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
H. Olschewski, H. A. Ghofrani, T. Schmehl, J. Winkler, H. Wilkens, M. M. Hoper, J. Behr, F.-X. Kleber, W. Seeger, and for the German PPH Study Group*
Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial
Ann Intern Med, March 21, 2000; 132(6): 435 - 443.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society